Currant treatmant and management of the acute phase of Peyronle's disease;Tratamiento y manejo actual de la fase aguda de la enfermedad de peyronie

Archivos Espanoles de Urologia

Volumn 62, Issue 8, 2009, Pages 614-622

  Vanni, Alex J ^a   Bennett, Nelson E ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Erectile dysfunction; Peyronie's disease

Indexed keywords

ACUTE DISEASE; ARTICLE; HUMAN; MALE; PEYRONIE DISEASE;

ACUTE DISEASE; HUMANS; MALE; PENILE INDURATION;

EID: 70449469254     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie's disease: results of a large survey. BJU Int. 2001 Nov; 88(7):727-730
2. 2. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol. 2004 Jun; 171(6 Pt l):2350-2353 (Pubitemid 38625468)
3. 3. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol. 2006 Jun;175(6):2115-8; discussion 8. (Pubitemid 43668536)
4. Greenfield JM, Levine LA. Peyronie's disease: etiology, epidemiology and medical treatment. Urol Clin North Am. 2005 Nov;32(4):469-78, vii.
5. Devine CJ, Jr., Somers KD, Jordan SG, Schlossberg SM. Proposal: trauma as the cause of the Peyronie's lesion. J Urol. 1997 Jan;157(1):285-290
6. Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction. J Urol. 1997 Oct;158(4): 1388-1390
7. Devine CJ, Jr., Horton CE. Peyronie's disease. Clin Plast Surg. 1988 Jul;15(3):405-409
8. Somers KD, Dawson DM. Fibrin deposition in Peyronie's disease plaque. J Urol. 1997 Jan;157(1):311-315
9. Lue TF. Peyronie's disease: an anatomically-based hypothesis and beyond. Int J Impôt Res. 2002 Oct;14(5):411-413
10. Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease. BJU Int. 2003 Jun;91(9):830-838
11. Davila HH, Magee TR, Zuniga FT, Rajfer J, Gonzalez-Cadavid NF. Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. Urology. 2005 Apr;65(4):645-648
12. Haag SM, Hauck EW, Szardening-Kirchner C, Diemer T, Cha ES, Weidner W, et al. Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie's disease. Eur Urol. 2007 Jan;51(1):255-261
13. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol. 1990 Dec;144(6): 1376-1379
14. 14. Ralph DJ, Schwartz G, Moore W, Pryor JP, Ebringer A, Bottazzo GF. The genetic and bacteriological aspects of Peyronie's disease. J Urol. 1997 Jan;157(1):291-294 (Pubitemid 26414976)
15. Nyberg LM, Jr., Bias WB, Hochberg MC, Walsh PC. Identification of an inherited form of Peyronie's disease with autosomal dominant inheritance and association with Dupuytren's contracture and histocompatibility B7 cross-reacting antigens. J Urol. 1982 Jul;128(1):48-51.
16. 16. Lyles KW, Gold DT, Newton RA, Parekh S, Shipp KM, Pieper CF, et al. Peyronie's disease is associated with Paget's disease of bone. J Bone Miner Res. 1997 Jun;12(6):929-934 (Pubitemid 27225003)
17. Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, et al. Peyronie's disease. J Sex Med. 2004 Jul;1(1):110-115
18. Scardino PL, Scott WW. The use of tocopherols in the treatment of Peyronie's disease. Ann NY Adad Sci. 1949(52):390-401.
19. Pryor JP, Farrell CF. Controlled clinical trial of vitamin E in Peyronie's disease. Prog Reprod Biol. 1983(9):41-45
20. Hashimoto K, Hisasue S, Kato R, Kobayashi K, Shimizu T, Tsukamoto T. Outcome analysis for conservative management of Peyronie's disease. Int J Urol. 2006 Mar;13(3):244-247
21. Zarafonetis CJD, Horrax TM. Treatment of Peyronie's disease with potassium para-aminobenzoate (Potaba). J Urol. 1959(81):770-772
22. Carson CC. Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it effective? Tech Urol. 1997Fall;3(3):135-139
23. Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebocontrolled, randomized study. Eur Urol. 2005 Apr;47(4):530-5; discussion 5-6.
24. Ehrlich H, Bornstein P. Microtubules in transcellular movement of procollagen. Nature. 1972(238):257-260
25. Harris EJ, Krane S. Effects of colchicines on collagenase in culture of rheumatoid synovium. Arthritis Rheum. 1971(14):669-684
26. 26. Akkus E, Carier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie's disease? A pilot study. Urology. 1994(44):291-295 (Pubitemid 24246173)
27. Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impôt Res. 2004 Jun;16(3):238-43.
28. Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP. The treatment of Peyronie's disease with tamoxifen. Br J Urol. 1992 Dec;70(6):648-651
29. Teloken C, Rhoden EL, Grazziotin TM, Teodósio Da Ros C, Sogari PR, Souto CAV. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol. 1999(162):2003-2005
30. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int. 2001 Jul;88(1):63-67
31. Garcia MM, Bella AJ, Lin GT, Lin C-S, Minor TX, Lue TF. The effect of pentoxyfylline on cultured human tunical fibroblasts harvested from patients with Peyronie's disease. Can J Urol. 2006(13):3099.
32. 32. Brant WO, Dean RC, Lue TF. Treatment of Peyronie's disease with oral Pentoxyfylline. Nat Clin Pract Urol. 2006;3(2):111-115 (Pubitemid 43239268)
33. 33. Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol. 2002 Dec;168(6):2483-2485 (Pubitemid 35402645)
34. 34. Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Giurioli A, Jannini EA, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol. 2004 Apr;171(4):1605-1608 (Pubitemid 38365431)
35. 35. Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol. 1993 Jan;149(1):56-58 (Pubitemid 23095473)
36. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study. J Sex Med. 2008 Jan;5(1):180-187
37. Roth M, Eickelberg O, Köhler E, Erne P, Block LH. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA. 1996 May 28;93(11):5478-5482
38. 38. Mulhall JP, Anderson MS, Lubrano T, Shankey TV. Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impôt Res. 2002 Oct;14(5):397-405. (Pubitemid 35285291)
39. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol. 1994 Jun;151(6):1522-1524
40. Rehman J, Benêt A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology. 1998 Apr;51(4):620-626
41. Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie's disease. Urology. 2007 Jun;69(6):1181-1184
42. 42. Lamprakopoulos A, Zorzos I, Lykourinas M. The use of betamethasone and hyaluronidase injections in the treatment of Peyronie's disease. Scand J Urol Nephrol. 2000 Dec;34(6):355-360 (Pubitemid 32066237)
43. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol. 1991;25(2):89-94.
44. 44. Judge IS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie's disease: a pilot study. Br J Urol. 1997 Jan;79(1):40-42 (Pubitemid 28318842)
45. 45. Wegner HE, Andresen R, Knispel HH, Miller K. Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie's disease. Eur Urol. 1997;32(2):190-193 (Pubitemid 27386960)
46. 46. Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol. 2006 Jul;176(1):394-398 (Pubitemid 43833173)
47. 47. Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T, Weidner W Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials. J Urol. 2004 Feb;171(2 Pt 1):740-745 (Pubitemid 38090471)
48. 48. Incrocci L, Wijnmaalen A, Slob AK, Hop WC, Levendag PC. Low-dose radiotherapy in 179 patients with Peyronie's disease: treatment outcome and current sexual functioning. Int J Radiât Oncol Biol Phys. 2000 Jul 15;47(5):1353-1356 (Pubitemid 30421189)
49. 49. Mulhall JP, Branch J, Lubrano T, Shankey TV. Radiation increases fibrogenic cytokine expression by Peyronie's disease fibroblasts. J Urol. 2003 Jul;170(1):281-284 (Pubitemid 36734479)
50. 50. Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study. J Sex Med. 2008 Jun;5(6):1468-1473 (Pubitemid 351803113)